In a report issued on October 31, Charles Rhyee from Cowen & Co. maintained a Buy rating on Express Scripts (NASDAQ: ESRX), with a price target of $88. The company’s shares closed yesterday at $96.74, close to its 52-week high of $98.98.
According to TipRanks.com, Rhyee is a 4-star analyst with an average return of 9.6% and a 52.6% success rate. Rhyee covers the Services sector, focusing on stocks such as Evolent Health, Rite Aid Corp, and UnitedHealth.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Express Scripts with a $96 average price target, which is a -0.8% downside from current levels. In a report issued on November 1, RBC Capital also maintained a Buy rating on the stock with a $101 price target.
See today’s analyst top recommended stocks >>
Based on Express Scripts’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $877 million. In comparison, last year the company had a net profit of $842 million.
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Express Scripts Holding Co. engages in the provision of pharmacy benefit management services. Its services include network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services.